New hope for Hard-to-Treat cancers: first human trial launches
NCT ID NCT06725758
First seen Jan 15, 2026 · Last updated May 16, 2026 · Updated 19 times
Summary
This study tests a new drug called ODM-212 in people with advanced solid tumours that cannot be cured with current treatments. The trial has two parts: first finding a safe dose, then testing that dose in more patients. About 315 adults with cancers like mesothelioma, lung, or colorectal cancer will take part. The main goal is to check for side effects and see how safe the drug is.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOURS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Oscar Lambret
RECRUITINGLille, France
Contact Email: •••••@•••••
Contact
-
Helsinki university Hospital
RECRUITINGHelsinki, Finland
Contact
Contact
-
Hospital 12 de Octubre
RECRUITINGMadrid, Spain
Contact
Contact Email: •••••@•••••
-
Hospital Virgen De La Macarena
RECRUITINGSeville, Spain
Contact
Contact Email: •••••@•••••
-
Institut Bergonie
RECRUITINGBordeaux, France
Contact Email: •••••@•••••
Contact
-
Institut Gustave Roussy
RECRUITINGVillejuif, France
Contact Email: •••••@•••••
Contact
-
Istituto Oncologico, Ospedale Bellinzona e Valli
RECRUITINGBellinzona, Canton Ticino, 6500, Switzerland
Contact Email: •••••@•••••
Contact
-
Jefferson University Hospital
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Email: •••••@•••••
Contact
-
Leicester Royal Infirmary
RECRUITINGLeicester, United Kingdom
Contact Email: •••••@•••••
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Email: •••••@•••••
Contact
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact Email: •••••@•••••
Contact
-
Oulu University Hospital
RECRUITINGOulu, Finland
Contact
Contact
-
Royal Marsden Hospital, London, UK
RECRUITINGLondon, SW36JJ, United Kingdom
Contact Email: •••••@•••••
Contact
-
Siteman Cancer Center
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Email: •••••@•••••
Contact
-
Turku University Hospital
RECRUITINGTurku, Finland
Contact
Contact
-
UC Irvine Health
RECRUITINGOrange, California, 92868, United States
Contact Email: •••••@•••••
Contact
-
University of Texas, MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Email: •••••@•••••
Contact
-
Valkyrie Clinical Trials
RECRUITINGLos Angeles, California, 90067, United States
Contact Email: •••••@•••••
Contact
-
Westchester Medical Center
RECRUITINGValhalla, New York, 10595, United States
Contact Email: •••••@•••••
Contact
-
Weston Park Hospital
RECRUITINGSheffield, United Kingdom
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.